Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1352-1357

  Armijos, Rodrigo X ^a   Margaret Weigel, M ^b   Aviles, Hernan ^b   Maldonado, Rocio ^b   Racines, Jose ^b  

^a UCE   (Ecuador)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LEISHMANIA VACCINE; PLACEBO;

ABSCESS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; FEVER; HEADACHE; HIGH RISK POPULATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROMASTIGOTE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN EDEMA; SKIN LEISHMANIASIS; SKIN TEST; SKIN ULCER; VACCINATION;

EID: 17344374265     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515265     Document Type: Article

References (12)

1. Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution of leishmaniasis in the New World. Am J Trop Med Hyg 1987; 41:687-725.
2. Grimaldi G Jr, Tesh RB. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev 1993; 6: 230-50.
3. Ashford RW, Desjeux P, de Raadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol Today 1992; 8:104-5.
4. Hashiguichi Y, Gomez EA. A general situation of leishmaniasis and its endemic region in Ecuador. In: Hashiguichi Y, ed. Studies on New World leishmaniasis and its transmission with particular reference to Ecuador. Japan: Kyowa Print, 1990:6-16; research report series 2.
5. Armijos RX, Weigel MM, Izurieta R, Racines J. Epidemiology of cutaneous leishmaniasis in an endemic area of subtropical Ecuador. Trop Med Int Health 1997;2:140-52.
6. Armijos RX, Weigel MM. Tegumentary American leishmaniasis. In: Hinostroza-Castaño D, ed. Infectious diseases. Quito: National Armed Forces Hospital/School of Medicine, Central University of Ecuador, 1994:255-68.
7. Hashiguichi Y, Gomez A. A review of Andean leishmaniasis. In: Hashiguichi Y, ed. Studies on New World leishmaniasis and its transmission with particular reference to Ecuador. Japan: Kyowa Print, 1992:5-10; research report series 3.
8. Alava JJ, Mora de Coello AF, Gomez EA. Studies on leishmaniasis in an endemic focus of Leishmania on the Pacific coast of Ecuador. In: Hashiguichi Y, ed. Studies on New World leishmaniasis and its transmission, with particular reference to Ecuador. Japan: Kyowa Print, 1992: 59-69; research report series 3.
9. Handman E, Mitchell GF. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA 1985;82:5910-4.
10. Liew FY, Singleton A, Cilliari E, Howard JG. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection. J Immunol 1985;35:2102-7.
11. Frommel D, Ogunkolade BW, Vouldoukis I, Monjour L. Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice. Infect Immun 1988;56:843-8.
12. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988;52: 3272-9.